BioAlberta has partnered with AxialBridge to support Alberta biotech and MedTech companies in expanding their clinical trials and R&D endeavors into the United Kingdom. This partnership aims to bridge the gap between Canadian and UK life science sectors.
AxialBridge, with its extensive experience in the UK healthcare market, will guide BioAlberta members through the regulatory and commercial pathways to enhance their UK operations. Robb Stoddard, President and CEO of BioAlberta, emphasized the unique positioning of AxialBridge due to its relationships and expertise in the UK.
The partnership will facilitate a bilateral exchange of opportunities and expertise. AxialBridge has successfully supported Canadian and UK companies in clinical trials, funding, and growth initiatives. This experience will be leveraged to identify and enable opportunities for Alberta businesses.
Jaspreet Grewal, CEO and Co-Founder of AxialBridge expressed pride in the partnership and its potential to foster innovation and collaboration. The partnership strengthens the long-standing relationship between Canada and the United Kingdom in life sciences, creating a valuable ecosystem for biotech and MedTech growth.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
